Microbiome Modulator

Lactobacillus acidophilus

Lactobacillus acidophilus

Evidence TierCWADA NOT PROHIBITED

tuneTypical Dose

1e9-1e10+ CFU/day (strain-specific)

watchEffect Window

4 weeks to 3 months

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

Lactobacillus acidophilus is a strain-specific probiotic with limited evidence, including a newer but still cautious signal in antibiotic-associated diarrhea support.

L. acidophilus should not be treated as a species-wide digestive solution. DDS-1 remains the cleaner lactose-intolerance strain, while newer LA85 data suggest possible benefit for antibiotic-associated diarrhea severity and stool stability without proving a broad prevention effect. Strain identity still matters more than the species name.

Strain-specific effects on lactose metabolism and gut signaling are plausible but inconsistent across strains.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Strain-dependent lactose-intolerance symptom support
  • Mixed efficacy across strains

Secondary Outcomes

  • Selected metabolic effects in combination contexts
  • Species-level claim limitations

Safety

Contraindications and Interactions

Contraindications

  • Severe immunocompromise without specialist guidance
  • Critical illness with invasive lines
  • Under 18 without supervision

Side effects

  • Gas/bloating
  • Stool-pattern changes
  • Rare infection risk in high-risk hosts

Interactions

  • Antibiotic timing conflict
  • Multi-probiotic confounding
  • High-prebiotic GI load overlap

Avoid if

  • No strain identifier on product
  • High-risk medical fragility
  • Inability to monitor response

Evidence

Study-level References

lactobacillus-acidophilus-SRC-001Randomized double-blind placebo-controlled crossover trial
Sourceopen_in_new

Pakdaman MN, et al. The effects of the DDS-1 strain of Lactobacillus on symptomatic relief for lactose intolerance: a randomized, double-blind, placebo-controlled, crossover clinical trial. Nutr J. 2016;15(1):56. doi:10.1186/s12937-016-0172-y. PMID:27207411.

Population: Adults with lactose intolerance

Dose protocol: Daily DDS-1 for 4 weeks per arm

Key findings: Significant reductions in multiple GI symptoms

Notes: Symptom-based endpoints under standardized challenge

Paper content

Significant reductions in multiple GI symptoms

lactobacillus-acidophilus-SRC-002Randomized controlled trial
Sourceopen_in_new

Saltzman JR, et al. A randomized trial of Lactobacillus acidophilus BG2FO4 to treat lactose intolerance. Am J Clin Nutr. 1999;69(1):140-146. doi:10.1093/ajcn/69.1.140. PMID:9925136.

Population: Lactose-maldigesting adults

Dose protocol: BG2FO4 twice daily for 7 days

Key findings: No significant improvement in hydrogen excretion or symptoms

Notes: Older trial, null findings

Paper content

No significant improvement in hydrogen excretion or symptoms

lactobacillus-acidophilus-SRC-003Randomized double-blind placebo-controlled trial
Sourceopen_in_new

Ramos MRZ, et al. Effects of Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 supplementation on nutritional and metabolic biomarkers in patients submitted to roux-en-y gastric bypass: a randomized, double-blind, placebo-controlled trial. Obes Surg. 2021;31(5):2105-2114. doi:10.1007/s11695-021-05222-2. PMID:33443719.

Population: Early postoperative RYGB patients

Dose protocol: Combination probiotic for 3 months

Key findings: Improved selected vitamin/lipid markers

Notes: Combination product and postoperative-specific context

Paper content

Improved selected vitamin/lipid markers

lactobacillus-acidophilus-SRC-004Randomized double-blind placebo-controlled trial
Sourceopen_in_new

Zhu J, Sun Y, Dong Y, et al. Efficacy and Safety of Lactobacillus acidophilus LA85 in Preventing Antibiotic-Associated Diarrhea: A Randomized, Placebo-Controlled Study. Food Sci Nutr. 2025;13(6):e70490. doi:10.1002/fsn3.70490. PMID:40548185.

Population: Adults receiving amoxicillin treatment during a probiotic prevention trial.

Dose protocol: LA85 at 2 × 10^9 CFU/day for 14 days during amoxicillin treatment

Key findings: Did not clearly lower overall diarrhea incidence, but shortened diarrhea duration and stabilized stool consistency, with a stronger younger-subgroup signal.

Notes: Useful modernization of the evidence base, but still too limited for broad species-level claims.

Paper content

This 2025 trial adds a cleaner modern endpoint for L. acidophilus than the older lactose-challenge literature alone. LA85 did not significantly lower antibiotic-associated diarrhea incidence overall, but it shortened diarrhea duration, stabilized stool consistency, improved GI quality of life, and showed a stronger signal in younger participants. That supports a cautious, strain-specific digestive use case while avoiding blanket species claims.

lactobacillus-acidophilus-SRC-005Multi-center, randomized, double-blind, placebo-controlled trial.
Sourceopen_in_new

Jang SJ, Park S, Lee K, et al. Lactobacillus acidophilus KBL409 improves serum indoxyl sulfate via gut microbial changes in a human study. NPJ Sci Food. 2026. doi:10.1038/s41538-026-00755-1. PMID:41698905.

Population: Individuals with chronic kidney disease.

Dose protocol: KBL409 at 1 × 10^10 CFU/day for 16 weeks in CKD patients

Key findings: Significantly lower serum indoxyl sulfate versus placebo, with favorable microbiome shifts reducing uremic toxin synthesis pathways.

Notes: Novel nephrology-adjacent application. Small sample (n=64), narrow population. Should not be extrapolated to general digestive health.

Paper content

This multi-center, double-blind RCT tested L. acidophilus KBL409 at 10 billion CFU daily for 16 weeks in 64 chronic kidney disease patients. The probiotic group showed significantly lower serum indoxyl sulfate, a uremic toxin associated with CKD progression and cardiovascular risk. Microbiome analysis revealed decreases in four bacterial genera correlated with reduced uremic toxin synthesis pathways. This is a novel strain-specific application of L. acidophilus in nephrology, providing the first controlled human evidence that a specific L. acidophilus strain can reduce a clinically relevant uremic toxin through microbiome modulation. The CKD population is narrow and results should not be extrapolated to general digestive health claims.

Guides

Setup

Help